July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement alternative pathway inhibition in a Phase I trial in 43 healthy volunteers outside the U.S. The company plans to submit an IND to FDA in 4Q19 for ACH-5228 to treat multiple alternative pathway diseases.

Chiasma jumps after Mycapssa meets in Phase III for acromegaly
Chiasma Inc. (NASDAQ:CHMA) climbed $1.66 (27%) to $7.86 Tuesday after reporting an oral formulation of somatostatin analog Mycapssa octreotide met the primary and secondary endpoints in the Phase III CHIASMA OPTIMAL trial for adults with acromegaly previously controlled by injectable somatostatin analogs. On the primary endpoint, 58% of patients treated with octreotide maintained their IGF-1 response after nine months compared to 19% of patients on placebo (p=0.008). Chiasma plans to submit an NDA to FDA by YE19...